Minnesota Medical Technologies Corporation, a Stewartville, Minnesota-based developer of continence care solutions, has raised $20.6 million in a Series A equity financing round led by HM Venture Partners and Southeast Minnesota Capital Partners.
Read More:Precision BioSciences Raises $7.5M in Funding
The company plans to use the funds to set up its U.S. commercial and distribution operations, grow its sales and marketing teams, and ensure financial stability for steady growth.
Minnesota Medical Technologies Corporation, a leader in continence care, was founded to tackle the often-overlooked issue of fecal incontinence. Working with Mayo Clinic gastroenterologist Adil Bharucha, MD, the company developed a simple, single-use device as an effective alternative to traditional absorbent products.
Fecal incontinence, also called “accidental bowel leakage,” affects over 2% of people worldwide—tens of millions—most of whom rely on adult diapers and pads instead of restorative treatments. This creates a large, largely untapped market for innovative, clinically proven solutions that improve quality of life.
After building a top-tier medical device manufacturing facility and completing a clinical trial at Mayo Clinic, StaySure™ received FDA clearance in July 2025. With regulatory approval in hand, Minnesota Medical Technologies is ready to grow its commercial presence. This Series A funding will help accelerate physician and patient education, expand distribution, and bring this innovative solution to a large, underserved global market.
“This funding is a major milestone for our company,” said David A. Jonas, CEO of Minnesota Medical Technologies. “With our investors’ support, we are ready to launch StaySure™ in the newly cleared U.S. market and grow our team. For the millions living with fecal incontinence, this means access to a safe, effective, and life-changing solution.”
About Minnesota Medical Technologies
Founded in 2015 by an experienced team with a strong track record, including leaders from Rochester Medical Corporation (sold in 2013 for $262M to CR Bard), Minnesota Medical Technologies Corporation develops and sells continence care products focused on comfort, quality, and performance. Its innovative StaySure™ is a clinically proven, single-use device designed to safely and effectively manage accidental bowel leakage and fecal incontinence.
By providing a discreet, patient-focused alternative to absorbent products and invasive surgeries, StaySure™ offers a unique solution in a large, underserved market. With experienced leadership, validated clinical data, and FDA clearance, the company is well-positioned to expand commercialization, improve patients’ lives, and create long-term shareholder value.
Read More:Ayar Labs Raises $500M in Series E Funding
